The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination ipilimumab/nivolumab for refractory Merkel cell carcinoma: A single-institution experience.
 
Mohammad Farooq
No Relationships to Disclose
 
Emily Ertmann
Employment - Boston Scientific (I)
Stock and Other Ownership Interests - Boston Scientific (I)
 
Gracia Vargas
No Relationships to Disclose
 
Neha Shafique
No Relationships to Disclose
 
Tara Mitchell
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst)
 
Lynn Schuchter
Consulting or Advisory Role - Incyte
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Stand up to Cancer
 
Ravi Amaravadi
Stock and Other Ownership Interests - Pinpoint Therapeutics
Consulting or Advisory Role - Tasca Therapeutics
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Deciphera (Inst); Merck KGaA (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I am inventor on 3 patents related to dimeric chloroquines. The patents are owned by UPenn and licensed to Pinpoint Therapeutics (Inst)
Travel, Accommodations, Expenses - Merck KGaA
 
Giorgos Karakousis
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Merck (Inst)
 
John Miura
Consulting or Advisory Role - Skyline Diagnostics; Skyline Diagnostics
Research Funding - Merck (Inst)